H
Herbert Noack
Researcher at Boehringer Ingelheim
Publications - 34
Citations - 1419
Herbert Noack is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Dabigatran & Warfarin. The author has an hindex of 18, co-authored 34 publications receiving 1265 citations. Previous affiliations of Herbert Noack include Rutgers University.
Papers
More filters
Journal ArticleDOI
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial
James D. Douketis,Jeff S. Healey,Martina Brueckmann,John W. Eikelboom,Michael D. Ezekowitz,Mandy Fraessdorf,Herbert Noack,Jonas Oldgren,Paul A. Reilly,Alex C. Spyropoulos,Lars Wallentin,Stuart J. Connolly +11 more
TL;DR: In patients who interrupted dabigatran or warfarin for a surgery/ procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabig atran orwarfarin interruption.
Journal ArticleDOI
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Frans Van de Werf,Martina Brueckmann,Stuart J. Connolly,Jeffrey Friedman,Christopher B. Granger,Sebastian Härtter,Ruth Harper,Arie Pieter Kappetein,Thorsten Lehr,Michael J. Mack,Herbert Noack,John W. Eikelboom +11 more
TL;DR: This study is the first study to test an alternative to warfarin in patients with mechanical heart valves and a definitive phase III study will be planned based on the results of this study.
Journal ArticleDOI
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Michael D. Ezekowitz,Rangadham Nagarakanti,Herbert Noack,Martina Brueckmann,Claire Litherland,Mark Jacobs,Andreas Clemens,Paul A. Reilly,Stuart J. Connolly,Salim Yusuf,Lars Wallentin +10 more
TL;DR: The RE-LY trial as mentioned in this paper compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients with atrial fibrillation, and the results showed that the drug significantly reduced the rate of atrial Fibrillation.
Journal ArticleDOI
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
TL;DR: Direct evidence suggests treatment with dabigatran etexilate offers benefit for the prevention of stroke, systemic embolism and mortality over antiplatelets and placebo, and trends toward reduced risk with both dabig atran e Texilate regimens were found for most clinical outcomes.
Journal ArticleDOI
Patient outcomes using the European label for dabigatran
Gregory Y.H. Lip,Andreas Clemens,Herbert Noack,Jorge Ferreira,Stuart J. Connolly,Salim Yusuf +5 more
TL;DR: A post-hoc simulation of dabigatran usage based on RE-LY trial dataset indicates that "EU label simulated dabig atran treatment" may be associated with superior efficacy and safety compared to warfarin, and are in support of the EU label and the 2012 European Society of Cardiology AF guideline recommendations.